Allergy/Asthma/Immunology

Top Story

FDA approves Fasenra for eosinophilic asthma maintenance therapy

November 15, 2017

The FDA has approved Fasenra for additional maintenance treatment of severe eosinophilic asthma in patients 12 years and older, according to the manufacturer release.

The approval of Fasenra (benralizumab, AstraZeneca) stems from the results of a program of studies, which included phase 3 exacerbation trials and a phase 3 oral corticosteroid-sparing trial. The respiratory biologic, which diminishes eosinophils within 24 hours, has not been approved for the treatment of other eosinophilic conditions, or the relief of acute bronchospasms or status asthmaticus.

In the JournalsPerspective

High dose peanut patch shows promise for peanut sensitivity

November 14, 2017
Patients with peanut sensitivity who wore a 250-µg epicutaneous immunotherapy-based peanut patch had a significant treatment response compared to patients wearing…
Meeting News

Novel hereditary angioedema therapy reduces attacks, treatment-related costs

November 10, 2017
BOSTON — A C1-esterase inhibitor (human) delivered subcutaneously for the treatment of long-term prophylaxis associated with hereditary angioedema decreased…
In the Journals

Recommendations inconsistent in pediatric asthma guidelines

November 8, 2017
Although national and international guidelines for the treatment of pediatric bronchiolitis have many similarities, less agreement is found in guidelines for the
More Headlines »
CME

Best of the Day™: Highlights in IBD from the World Congress of Gastroenterology at ACG2017

Supported by educational grants from: Celgene Corporation and Salix Pharmaceuticals, Inc.

Since the introduction of newer targeted therapies, approaches to the treatment of IBD have grown significantly more…
More »
GI Bookshelf

Chapter 22: Nutritional Support In Acute Pancreatitis

From Clinical Nutrition in Gastrointestinal Disease
More »
Resource Centers
American College of Allergy, Asthma and Immunology Annual Meeting

American College of Allergy, Asthma and Immunology Annual Meeting

Video
Meeting News Coverage

VIDEO: Long-term Dupixent plus topical corticosteroid treatment effective for AD

March 7, 2017
More »